Form 4: Regulus Therapeutics Director William H. Rastetter Receives Stock Options

Director William H. Rastetter received 62,500 Restricted Stock Units in Regulus Therapeutics Inc.

Summary

• On April 30, 2025, William H. Rastetter, a director of Regulus Therapeutics Inc., was granted 62,500 Restricted Stock Units.
• These units vest in equal monthly installments over 12 months from the grant date.
• Following this transaction, Rastetter indirectly owns 101,556 shares of common stock through The Rastetter Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company over the next year.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to incentivize the director.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Regulus Therapeutics, RGLS, William H. Rastetter, Restricted Stock Units, Director, Form 4, Beneficial Ownership, Insider Trading